Quest and LabCorp recently highlighted increased compensation costs while other industry observers have seen salaries rising for specialties like molecular.
Diagnostics revenues for the fourth quarter were $1.76 billion, up 4 percent from $1.69 billion in the same quarter last year.
The company said that it experienced a breach of an internal data system used by its integrated oncology business and that it is investigating the incident.
A pair of lawyers familiar with the case said that while ACLA might not win the legal battle, its lawsuit could aid efforts to get a legal fix to the law.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
While legislation and lawsuits sought to blunt PAMA's impact, labs also employed new technologies and strategies to cope with anticipated price cuts.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
News items from the in vitro diagnostics industry for the week of Nov. 18, 2019.